Study using Nexalin’s proprietary DIFS ™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate Nexalin’s prior clinical data and support the Company’s differentiated, non-invasive approach to deep frequency-based neurostimulation No serious adverse events, seizures or manic/hypomanic switches were reported, reinforcing the favorable tolerability profile of Nexalin’s technology HOUSTON, June 10, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of an 8-week, single-center, prospective, open-label clinical trial evaluating Nexalin’s proprietary 15 milliamp (mA), 77.5 Hz neurostimulation protocol in adults with generalized anxiety disorder and comorbid insomnia. The clinical trial was conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Participants received 20 sessions of transcranial alternating current stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. The completed trial demonstrated rapid, large-magnitude and durable improvements across multiple high-burden neuropsychiatric domains, including anxiety, depressive symptoms, insomnia and quality of life. Importantly, improvements were observed early in the treatment course, continued through the end of treatment, and were maintained at 8-week follow-up. “This is another major clinical milestone for Nexalin and another powerful validation point for our proprietary non-invasive treatment platform,” said Mark White, Chief Executive Officer of Nexalin Technology. “These results continue to affirm the positive clinical signals observed in prior Nexalin studies and strengthen our conviction that Nexalin is developing a fundamentally differentiated and advanced neuro-technology platform, not a ‘me-too’ neurostimulation device. We believe our non-invasive, frequency-based approach has the potential to represent a breakthrough in the treatment of neuropsychiatric conditions where patients urgently need new options.” Key results from the completed pilot trial include: 77.8% anxiety response rate at end of treatment: Anxiety response rates reached 77.8% at Session 20. Rapid anxiety improvement: Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points by Session 5. Durable anxiety benefit: HAM-A scores decreased by 18.30 points by Session 20, with reductions maintained at 8-week follow-up. Depressive symptom improvement: Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by Session 20. High depressive symptom response and remission: HAMD response and remission rates both reached 66.7% at the end of treatment. Sustained insomnia improvement: Pittsburgh Sleep Quality Index (PSQI) scores improved significantly at the end of treatment and remained significantly improved at 8-week follow-up, with large effect sizes reported. Quality-of-life improvement: Overall quality of life improved significantly at the end of treatment, with favorable directional trends across additional quality-of-life domains. Favorable tolerability profile: No serious adverse events, seizures or manic/hypomanic switches were reported. Mr. White continued, “Mental health remains one of the largest and most urgent healthcare challenges in the world. Existing treatment options often involve delayed onset of benefit, incomplete response, side effects, adherence challenges, or limited durability. Nexalin is pursuing a new category of non-invasive, drug-free neurostimulation techniques designed to address these limitations in current non-invasive stimulators. We believe these data provide additional evidence that our platform can deliver meaningful clinical improvements across interconnected symptoms that commonly occur together, including anxiety, mood disruption, insomnia, and impaired quality of life.” Nexalin believes the completed Brazilian trial provides important support for the Company’s broader clinical and sales strategy in Brazil. The Company believes the data are particularly meaningful because they build upon and further validate prior published Nexalin clinical findings. Nexalin is currently preparing a product launch and sales campaign in Brazil that will benefit from the Brazilian trial. “These findings are highly encouraging because they show improvement across multiple clinically relevant outcomes, not just a single endpoint,” said Dr. David Owens, Chief Medical Officer of Nexalin Technology. “The trial demonstrated rapid improvement in anxiety and depressive symptoms, sustained improvement in sleep quality, and a favorable tolerability profile. While these results should be interpreted in the context of an open-la